In 2013, the IAS HIV Cure resource tracking group joined forces with AVAC to estimate global investments in HIV cure research. To date, this collaboration has yielded seven years of estimates for cure research investment from 2012 to 2018.
The Working Group estimates that in 2018, US$323.9 million was invested in cure research, representing a 12 percent increase over the US$288.8 million invested in 2017, and an increase of 268 percent over the US$88.1 million invested in 2012.
The majority of investments (US$302.4 million) came from the public sector with US$19.7 million invested by philanthropies such as Aidsfonds, amfAR, the Bill and Melinda Gates Foundation, CANFAR, Institut Pasteur, Sidaction and Wellcome Trust. Despite outreach by the Working Group, few companies responded to the survey, whilst several companies are known to have active cure research programmes, resulting in a signficant underestimation for commercial investment in cure research.
Download the full report, Global Investment in HIV Cure Research and Development in 2018.